Taro Pharmaceuticals North America, Inc.

Taro Pharmaceuticals U.s.a., Inc.

Pulmonem Inc.

Taro Pharmaceutical Industries Limited

Taro Pharmaceutical North America, Inc.

Satish Asotra

Shen Gao

Xiaoli Wang

Daniel A Moros

Avraham Yacobi

Houfar Sekhavat

Zoltan Bodor

Kalpana Vanam

Theophilus Van Den Heuvel

Jerzy Zadykowicz

Kalpana R Vanam

A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

Method of treating a person afflicted with a respiratory condition and pharmaceutical formulation including dapsone

Method of treating a person afflicted with COVID-19 and pharmaceutical formulation including dapsone

A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

Dapsone formulations and methods of using same

The present invention provides for a storage stable pharmaceutical liquid solution for oral administration having a pharmaceutically effective amount of an antihistamine and having a purity equal to or greater than about 99% by weight-based HPLC assay, residual solvents of less than about 0.5%, and a total impurity of less than about 0.2%. The storage stable solution preferably contains cetirizine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid solution as well as a method of treating a mammal with a therapeutically effective amount of cetirizine in the stable pharmaceutical liquid solution.

Anti-histamine compositions and use thereof

The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.

Oral suspension of prednisolone acetate

The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).

Stabilizing compositions for antibiotics and methods of use

The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may be dispersed or dissolved, and therefore allows for easier preparation and formulation of the pharmaceutical composition.

Spill resistant formulations containing clays

The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension.

Stable loratadine spill resistant formulation

An article of manufacture comprises a) a squeezable bottle having an outlet, b) a plug in the bottle, the plug comprising an upper surface with a protruding nipple having a neck, and a top and an orifice communicating with a smooth tubular channel sized to permit a semi-solid formulation to be squeezed out of the bottle and through the channel and orifice without dislodging the cap, the neck of the nipple having a protruding height slightly greater than the thickness of a spoon, and the neck of the nipple and the flat upper surface forming a notch which engages with the edge of a spoon, the orifice forming a sharp intersection with the top of the nipple sufficient to cut flow of the formulation cleanly when pressure ceases, and the junction of the top of the nipple with the nipple neck having a bevel, and c) a child resistant cap to cover the orifice when the formulation is not in use, the cap sealing the orifice without abrading the nipple.

Growing community of inventors

Brampton, Canada

Satish Asotra